EP-1571: Is Neoadjuvant ADT Necessary for Intermediate-Risk Prostate Cancer Treated with Proton Therapy?

Authors :: Fumiko Nagano
T. Waki
Nobukazu Fuwa
M. Murakami
Nor Shazrina Sulaiman
Tomoaki Okimoto
Kuniaki Katsui
Yusuke Demizu
Kazuki Terashima
Yasue Niwa
Osamu Fujii
Masaru Takagi
Masayuki Mima
Dongcun Jin
Source :: Radiotherapy and Oncology. 127:S846-S847
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Oncology
Prostate cancer
medicine.medical_specialty
business.industry
Internal medicine
medicine
Radiology, Nuclear Medicine and imaging
Hematology
medicine.disease
Intermediate risk
business
Proton therapy

Tools